Citations (42)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Chanthawat Patikorn, Warittakorn Kategeaw, Johnna Perdrizet, Xiuyan Li & Nathorn Chaiyakunapruk. (2023) Implementation challenges and real-world impacts of switching pediatric vaccines: A global systematic literature review. Human Vaccines & Immunotherapeutics 19:1.
Read now
Read now
Ting Zhao, Jing Li, Hongyuan Shi, Hui Ye, Rufei Ma, Yuting Fu, Xiaochang Liu, Guoliang Li, Xiaolei Yang, Zhimei Zhao & Jingsi Yang. (2021) Reduced mucosal immunity to poliovirus after cessation of trivalent oral polio vaccine. Human Vaccines & Immunotherapeutics 17:8, pages 2560-2567.
Read now
Read now
Guodong Kang, Fenyang Tang, Zhiguo Wang, Ran Hu, Jing Yu & Jun Gao. (2021) Surveillance of adverse events following the introduction of inactivated poliovirus vaccine made from Sabin strains (sIPV) to the Chinese EPI and a comparison with adverse events following inactivated poliovirus vaccine made from wild strains (wIPV) in Jiangsu, China. Human Vaccines & Immunotherapeutics 17:8, pages 2568-2574.
Read now
Read now
Kai Chu, Weixiao Han, Deyu Jiang, Zhiwei Jiang, Taotao Zhu, Wenbo Xu, Yuemei Hu & Gang Zeng. (2021) Cross-neutralization Capacity of Immune Serum from Different Dosage of Sabin Inactivated Poliovirus Vaccine Immunization against Multiple Individual Polioviruses. Expert Review of Vaccines 20:6, pages 761-767.
Read now
Read now
Jingjun Qiu, Yunkai Yang, Lirong Huang, Ling Wang, Zhiwei Jiang, Jian Gong, Wei Wang, Hongyan Wang, Shaohong Guo, Chanjuan Li, Shuyuan Wei, Zhaojun Mo & Jielai Xia. (2017) Immunogenicity and safety evaluation of bivalent types 1 and 3 oral poliovirus vaccine by comparing different poliomyelitis vaccination schedules in China: A randomized controlled non-inferiority clinical trial. Human Vaccines & Immunotherapeutics 13:6, pages 1359-1368.
Read now
Read now
Articles from other publishers (37)
Arend Voorman, Hil Lyons, Faisal Shuaib, Usman S Adamu, Charles Korir, Tesfaye Erbeto, Ananda S Bandyopadhyay & Samuel Okiror. (2023) Impact of Supplementary Immunization Activities using Novel Oral Polio Vaccine Type 2 during a Large outbreak of Circulating Vaccine-Derived Poliovirus in Nigeria. The Journal of Infectious Diseases.
Crossref
Crossref
Alda Morais, Joana Morais, Miguel Felix, Zoraima Neto, Valódia Madaleno, Abubakar Sadiq Umar, Nirakar Panda, Fekadu Lemma, José Alexandre Lifande Chivale, Danielle Graça Cavalcante, Elizabeth Davlantes, Margherita Ghiselli, Catherine Espinosa, Ari Whiteman, Jane Iber, Elizabeth Henderson, Kelley Bullard, Jaume Jorba, Cara C. Burns, Ousmane Diop, Nicksy Gumede, Lerato Seakamela, Wayne Howard & Alean Frawley. (2023) Genetic and epidemiological description of an outbreak of circulating vaccine-derived polio-virus type 2 (cVDPV2) in Angola, 2019–2020. Vaccine 41, pages A48-A57.
Crossref
Crossref
Jorge Quarleri. (2022) Poliomyelitis is a current challenge: long-term sequelae and circulating vaccine-derived poliovirus. GeroScience 45:2, pages 707-717.
Crossref
Crossref
Md Taufiqul Islam, Kashmira Date, Ashraful Islam Khan, Taufiqur Rahman Bhuiyan, Zahid Hasan Khan, Shamim Ahmed, Motaher Hossain, Fatema Khaton, K Zaman, Nigel A J McMillan, Abhijeet Anand, Qian An, Chenhua Zhang, William C Weldon, Alexander Yu, Stephen Luby & Firdausi Qadri. (2023) Co-administration of Oral Cholera Vaccine With Oral Polio Vaccine Among Bangladeshi Young Children: A Randomized Controlled Open Label Trial to Assess Interference. Clinical Infectious Diseases 76:2, pages 263-270.
Crossref
Crossref
Samir V. Sodha, Thomas Cherian, Patrick Lydon, Ann Lindstrand, Natasha S. Crowcroft, Lisa Menning, Rudolf Eggers, Jean-Marie Okwo-Bele & Katherine L. O’Brien. 2023. Plotkin's Vaccines. Plotkin's Vaccines
1578
1602.e6
.
Kouichi Kitamura & Hiroyuki Shimizu. (2022) Outbreaks of Circulating Vaccine-Derived Poliovirus in the World Health Organization Western Pacific Region, 2000–2021. Japanese Journal of Infectious Diseases 75:5, pages 431-444.
Crossref
Crossref
Robert K. M. Choy, A. Louis Bourgeois, Christian F. Ockenhouse, Richard I. Walker, Rebecca L. Sheets & Jorge Flores. (2022) Controlled Human Infection Models To Accelerate Vaccine Development. Clinical Microbiology Reviews 35:3.
Crossref
Crossref
Yi An Lai, Xin Chen, Mohana Kunasekaran, Bayzidur Rahman & Chandini Raina MacIntyre. (2022) Global epidemiology of vaccine-derived poliovirus 2016–2021: A descriptive analysis and retrospective case-control study. eClinicalMedicine 50, pages 101508.
Crossref
Crossref
Huakun Lv, Xuejiao Pan, Hui Liang, Yaping Chen, Ying Wang, Fuxing Chen, Linzhi Shen & Yu Hu. (2022) A Comparison with Adverse Events Following Immunization Associated with Sabin-Strains and Salk-Strains Inactivated Polio Vaccines in Zhejiang Province, China. Vaccines 10:2, pages 319.
Crossref
Crossref
Ruth I. Connor, Elizabeth B. Brickley, Wendy F. Wieland-Alter, Margaret E. Ackerman, Joshua A. Weiner, John F. Modlin, Ananda S. Bandyopadhyay & Peter F. Wright. (2022) Mucosal immunity to poliovirus. Mucosal Immunology 15:1, pages 1-9.
Crossref
Crossref
Marie-Line Joffret, Joël Wilfried Doté, Nicksy Gumede, Marco Vignuzzi, Maël Bessaud & Ionela Gouandjika-Vasilache. (2021) Vaccine-Derived Polioviruses, Central African Republic, 2019. Emerging Infectious Diseases 27:2, pages 620-623.
Crossref
Crossref
Mirembe Rachel Faith, Babirye Juliet, Nathan Tumuhamye, Tumwebaze Mathias & Emma Sacks. (2020) Factors associated with the utilization of inactivated polio vaccine among children aged 12 to 23 months in Kalungu District, Uganda. Health Policy and Planning 35:Supplement_1, pages i30-i37.
Crossref
Crossref
Arie Voorman, Muhammad Atif Habib, Imtiaz Hussain, Rana Muhammad Safdar, Jamal A. Ahmed, William C. Weldon, Imran Ahmed, Muhammad Umer, Jeffrey Partridge & Sajid Bashir Soofi. (2020) Immunity and field efficacy of type 2-containing polio vaccines after cessation of trivalent oral polio vaccine: A population-based serological study in Pakistan. Vaccine: X 5, pages 100067.
Crossref
Crossref
Olubukola T. Idoko, Kinga K. Smolen, Oghenebrume Wariri, Abdulazeez Imam, Casey P. Shannon, Tida Dibassey, Joann Diray-Arce, Alansana Darboe, Julia Strandmark, Rym Ben-Othman, Oludare A. Odumade, Kerry McEnaney, Nelly Amenyogbe, William S. Pomat, Simon van Haren, Guzmán Sanchez-Schmitz, Ryan R. Brinkman, Hanno Steen, Robert E. W. Hancock, Scott J. Tebbutt, Peter C. Richmond, Anita H. J. van den Biggelaar, Tobias R. Kollmann, Ofer Levy, Al Ozonoff & Beate Kampmann. (2020) Clinical Protocol for a Longitudinal Cohort Study Employing Systems Biology to Identify Markers of Vaccine Immunogenicity in Newborn Infants in The Gambia and Papua New Guinea. Frontiers in Pediatrics 8.
Crossref
Crossref
Gregory J. Tobin, John K. Tobin, Elena K. Gaidamakova, Taralyn J. Wiggins, Ruth V. Bushnell, Wai-Ming Lee, Vera Y. Matrosova, Stephen J. Dollery, Heather N. Meeks, Diana Kouiavskaia, Konstantin Chumakov & Michael J. Daly. (2020) A novel gamma radiation-inactivated sabin-based polio vaccine. PLOS ONE 15:1, pages e0228006.
Crossref
Crossref
Mustafa A. M. Salih & Peter B. Kang. 2020. Clinical Child Neurology. Clinical Child Neurology
1167
1180
.
Agustín Ciapponi, Ariel Bardach, Lucila Rey Ares, Demián Glujovsky, María Luisa Cafferata, Silvana Cesaroni & Aikant Bhatti. (2019) Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis. Cochrane Database of Systematic Reviews 2019:12.
Crossref
Crossref
Mohammadreza Shaghaghi, Shohreh Shahmahmoodi, Ali Nili, Hassan Abolhassani, Seyedeh Panid Madani, Ahmad Nejati, Maryam Yousefi, Yaghoob M. Kandelousi, Mona Irannejad, Shiva Shaghaghi, Seyed Mohsen Zahraei, Sussan Mahmoudi, Mohammad Mehdi Gouya, Reza Yazdani, Gholamreza Azizi, Nima Parvaneh & Asghar Aghamohammadi. (2019) Vaccine-Derived Poliovirus Infection among Patients with Primary Immunodeficiency and Effect of Patient Screening on Disease Outcomes, Iran. Emerging Infectious Diseases 25:11, pages 2005-2012.
Crossref
Crossref
Yuemei Hu, Kangwei Xu, Weixiao Han, Kai Chu, Deyu Jiang, Jianfeng Wang, Xiaohui Tian, Zhifang Ying, Ying Zhang, Changgui Li & Fengcai Zhu. (2019) Safety and Immunogenicity of Sabin Strain Inactivated Poliovirus Vaccine Compared With Salk Strain Inactivated Poliovirus Vaccine, in Different Sequential Schedules With Bivalent Oral Poliovirus Vaccine: Randomized Controlled Noninferiority Clinical Trials in China. Open Forum Infectious Diseases 6:10.
Crossref
Crossref
Xiangdong Peng, Xiaojiang Hu & Miguel A. Salazar. (2019) First case in China of vaccine-associated poliomyelitis after sequential Inactivated and bivalent oral polio vaccination. Vaccine 37:5, pages 751-754.
Crossref
Crossref
Sayan Dutta Gupta & Anindita Banerjee. 2019. Viral Polymerases. Viral Polymerases
135
154
.
Nermeen M. Galal, Safaa Meshaal, Rabab ElHawary, Eman Nasr, Laila Bassiouni, Humayun Ashghar, Noha H. Farag, Ondrej Mach, Cara Burns, Jane Iber, Qi Chen & Aisha ElMarsafy. (2018) Poliovirus excretion following vaccination with live poliovirus vaccine in patients with primary immunodeficiency disorders: clinicians’ perspectives in the endgame plan for polio eradication. BMC Research Notes 11:1.
Crossref
Crossref
Mary Bridget Nanteza, Barnabas Bakamutumaho, Annet Kisakye, Prossy Namuwulya, Henry Bukenya, Edson Katushabe, Josephine Bwogi, Charles Rutebarika Byabamazima, Raffaella Williams & Nicksy Gumede. (2018) The detection of 3 ambiguous type 2 vaccine-derived polioviruses (VDPV2s) in Uganda. Virology Journal 15:1.
Crossref
Crossref
Bassey Enya Bassey, Fiona Braka, Rui Gama Vaz, William Komakech, Sylvester Toritseju Maleghemi, Richard Koko, Thompson Igbu, Faith Ireye, Sylvester Agwai, Godwin Ubong Akpan, Sisay Gashu Tegegne, Abdul-Aziz Garba Mohammed & Angela Okocha-Ejeko. (2018) The global switch from trivalent oral polio vaccine (tOPV) to bivalent oral polio vaccine (bOPV): facts, experiences and lessons learned from the south-south zone; Nigeria, April 2016. BMC Infectious Diseases 18:1.
Crossref
Crossref
Xiangdong Peng, Xiaojiang Hu & Miguel A Salazar. (2018) On reducing the risk of vaccine-associated paralytic poliomyelitis in the global transition from oral to inactivated poliovirus vaccine. The Lancet 392:10147, pages 610-612.
Crossref
Crossref
Justin G. Trogdon, Paul Shafer, Brianna Lindsay & Tamera Coyne-Beasley. (2018) Determinants of the receipt of the 9-valent human papillomavirus vaccine in the first year after introduction in North Carolina. Vaccine 36:10, pages 1310-1315.
Crossref
Crossref
Justin G. Trogdon, Paul Shafer, Brianna Lindsay & Tamera Coyne-Beasley. (2018) Impact of introduction of the 9-valent human papillomavirus vaccine on vaccination coverage of youth in North Carolina. Vaccine 36:10, pages 1304-1309.
Crossref
Crossref
Sunil Bahl, Pankaj Bhatnagar, Roland W Sutter, Sigrun Roesel & Michel Zaffran. (2018) Global Polio Eradication – Way Ahead. The Indian Journal of Pediatrics 85:2, pages 124-131.
Crossref
Crossref
Kevin A. McCarthy, Guillaume Chabot-Couture, Michael Famulare, Hil M. Lyons & Laina D. Mercer. (2017) The risk of type 2 oral polio vaccine use in post-cessation outbreak response. BMC Medicine 15:1.
Crossref
Crossref
Steve J. Kroiss, Michael Famulare, Hil Lyons, Kevin A. McCarthy, Laina D. Mercer & Guillaume Chabot-Couture. (2017) Evaluating cessation of the type 2 oral polio vaccine by modeling pre- and post-cessation detection rates. Vaccine 35:42, pages 5674-5681.
Crossref
Crossref
Manish Patel & Stephen Cochi. (2017) Addressing the Challenges and Opportunities of the Polio Endgame: Lessons for the Future. The Journal of Infectious Diseases 216:suppl_1, pages S1-S8.
Crossref
Crossref
Alejandro Ramirez GonzalezMargaret FarrellLisa MenningJulie GaronHans Everts, Lee M. Hampton, Samantha B. Dolan, Stephanie ShendaleSarah WanyoikeChantal Laroche VeiraGaël Maufras du Châtellier, Feyrouz KurjiJennifer Rubin, Liliane BoualamDiana Chang BlancManish Patel. (2017) Implementing the Synchronized Global Switch from Trivalent to Bivalent Oral Polio Vaccines—Lessons Learned From the Global Perspective. The Journal of Infectious Diseases 216:suppl_1, pages S183-S192.
Crossref
Crossref
Santosh Gurung, Jennifer B Harris, Abu Obeida Eltayeb, Lee M Hampton, Sergey Diorditsa, Tigran Avagyan & W. William Schluter. (2017) Experience With Inactivated Polio Vaccine Introduction and the “Switch” From Trivalent to Bivalent Oral Polio Vaccine in the World Health Organization’s Western Pacific Region. The Journal of Infectious Diseases 216:suppl_1, pages S101-S108.
Crossref
Crossref
Cristina Pedreira, Elizabeth Thrush & Barbara Jauregui. (2017) Systematization of the Introduction of IPV and Switch from tOPV to bOPV in the Americas. The Journal of Infectious Diseases 216:suppl_1, pages S76-S85.
Crossref
Crossref
Julie Garon & Manish Patel. (2017) The polio endgame: rationale behind the change in immunisation. Archives of Disease in Childhood 102:4, pages 362-365.
Crossref
Crossref
Mia C. HikkeGorben P. Pijlman. (2017) Veterinary Replicon Vaccines. Annual Review of Animal Biosciences 5:1, pages 89-109.
Crossref
Crossref
Radboud J Duintjer Tebbens & Kimberly M Thompson. (2016) The potential benefits of a new poliovirus vaccine for long-term poliovirus risk management. Future Microbiology 11:12, pages 1549-1561.
Crossref
Crossref